Key Points
- USANA director Frederic Winssinger sold 2,000 shares on November 10 at an average price of $19.21 for proceeds of $38,420, leaving him with 5,986 shares — a 25.04% reduction in his ownership.
- Recent company and trading data: USNA opened at $19.19 with 50‑ and 200‑day SMAs of $25.36 and $28.64, market cap ~$350.7M; Q3 results showed $0.56 EPS and $200.22M revenue, and Q3 2025 guidance was set at -0.150 to 0.150 EPS.
- Analyst sentiment has weakened, with downgrades from Zacks, Weiss and Wall Street Zen and a MarketBeat average rating of "Reduce" and an average price target of $36.00.
USANA Health Sciences, Inc. (NYSE:USNA - Get Free Report) Director Frederic Winssinger sold 2,000 shares of USANA Health Sciences stock in a transaction that occurred on Monday, November 10th. The shares were sold at an average price of $19.21, for a total transaction of $38,420.00. Following the transaction, the director directly owned 5,986 shares in the company, valued at approximately $114,991.06. This trade represents a 25.04% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.
USANA Health Sciences Trading Up 0.3%
NYSE:USNA opened at $19.19 on Tuesday. The firm's fifty day simple moving average is $25.36 and its 200 day simple moving average is $28.64. USANA Health Sciences, Inc. has a twelve month low of $18.69 and a twelve month high of $41.83. The firm has a market capitalization of $350.72 million, a price-to-earnings ratio of 21.80, a PEG ratio of 0.94 and a beta of 0.61.
USANA Health Sciences (NYSE:USNA - Get Free Report) last issued its quarterly earnings data on Thursday, October 9th. The company reported $0.56 EPS for the quarter. The company had revenue of $200.22 million for the quarter. USANA Health Sciences had a return on equity of 6.96% and a net margin of 1.86%. USANA Health Sciences has set its Q3 2025 guidance at -0.150--0.150 EPS. On average, analysts predict that USANA Health Sciences, Inc. will post 2.45 earnings per share for the current year.
Analyst Upgrades and Downgrades
USNA has been the topic of several analyst reports. Zacks Research downgraded shares of USANA Health Sciences from a "hold" rating to a "strong sell" rating in a research note on Tuesday, October 21st. Weiss Ratings reissued a "sell (d+)" rating on shares of USANA Health Sciences in a report on Wednesday, October 8th. Finally, Wall Street Zen downgraded USANA Health Sciences from a "buy" rating to a "hold" rating in a report on Saturday, October 11th. Two research analysts have rated the stock with a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Reduce" and an average price target of $36.00.
Get Our Latest Analysis on USANA Health Sciences
Institutional Investors Weigh In On USANA Health Sciences
Institutional investors have recently made changes to their positions in the company. PNC Financial Services Group Inc. boosted its holdings in USANA Health Sciences by 339.6% in the first quarter. PNC Financial Services Group Inc. now owns 998 shares of the company's stock worth $27,000 after purchasing an additional 771 shares during the period. Tower Research Capital LLC TRC grew its position in shares of USANA Health Sciences by 382.5% during the 2nd quarter. Tower Research Capital LLC TRC now owns 2,398 shares of the company's stock valued at $73,000 after buying an additional 1,901 shares during the last quarter. CWM LLC raised its stake in USANA Health Sciences by 109.7% during the second quarter. CWM LLC now owns 2,762 shares of the company's stock worth $84,000 after acquiring an additional 1,445 shares during the period. AlphaQuest LLC lifted its holdings in USANA Health Sciences by 300.9% in the first quarter. AlphaQuest LLC now owns 3,412 shares of the company's stock worth $92,000 after acquiring an additional 2,561 shares during the last quarter. Finally, Quantbot Technologies LP boosted its stake in USANA Health Sciences by 19.5% in the second quarter. Quantbot Technologies LP now owns 3,957 shares of the company's stock valued at $121,000 after acquiring an additional 646 shares during the period. 54.25% of the stock is currently owned by institutional investors.
USANA Health Sciences Company Profile
(
Get Free Report)
USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
